Membrane-targeted complement inhibitors

G P Smith; R A G Smith

Membrane-targeted complement inhibitors

G P Smith, R A G Smith

King's College London

Research output: Contribution to journal › Literature review › peer-review

66 Citations (Scopus)

Abstract

Undesirable complement activation contributes to the pathology of many human diseases by damaging tissue and promoting inflammation. Because complement-mediated damage is caused by the deposition of complement components on the cell surface, several strategies have been devised to target complement regulator proteins to cell membranes. These strategies have resulted in engineered proteins that have improved potency in vitro and enhanced therapeutic benefit in animal models of disease. One membrane-targeted complement inhibitor has now entered clinical development and this class of second-generation agents may provide effective therapies for the treatment of a variety of disease states. (C) 2001 Elsevier Science Ltd. All rights reserved

Original language	English
Pages (from-to)	249 - 255
Number of pages	7
Journal	Molecular Immunology
Volume	38
Issue number	2-3
Publication status	Published - 2001

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{029407d5367149518896e92fd15b2edf,

title = "Membrane-targeted complement inhibitors",

abstract = "Undesirable complement activation contributes to the pathology of many human diseases by damaging tissue and promoting inflammation. Because complement-mediated damage is caused by the deposition of complement components on the cell surface, several strategies have been devised to target complement regulator proteins to cell membranes. These strategies have resulted in engineered proteins that have improved potency in vitro and enhanced therapeutic benefit in animal models of disease. One membrane-targeted complement inhibitor has now entered clinical development and this class of second-generation agents may provide effective therapies for the treatment of a variety of disease states. (C) 2001 Elsevier Science Ltd. All rights reserved",

author = "Smith, {G P} and Smith, {R A G}",

year = "2001",

language = "English",

volume = "38",

pages = "249 -- 255",

journal = "Molecular Immunology",

publisher = "Elsevier Limited",

number = "2-3",

}

TY - JOUR

T1 - Membrane-targeted complement inhibitors

AU - Smith, G P

AU - Smith, R A G

PY - 2001

Y1 - 2001

N2 - Undesirable complement activation contributes to the pathology of many human diseases by damaging tissue and promoting inflammation. Because complement-mediated damage is caused by the deposition of complement components on the cell surface, several strategies have been devised to target complement regulator proteins to cell membranes. These strategies have resulted in engineered proteins that have improved potency in vitro and enhanced therapeutic benefit in animal models of disease. One membrane-targeted complement inhibitor has now entered clinical development and this class of second-generation agents may provide effective therapies for the treatment of a variety of disease states. (C) 2001 Elsevier Science Ltd. All rights reserved

AB - Undesirable complement activation contributes to the pathology of many human diseases by damaging tissue and promoting inflammation. Because complement-mediated damage is caused by the deposition of complement components on the cell surface, several strategies have been devised to target complement regulator proteins to cell membranes. These strategies have resulted in engineered proteins that have improved potency in vitro and enhanced therapeutic benefit in animal models of disease. One membrane-targeted complement inhibitor has now entered clinical development and this class of second-generation agents may provide effective therapies for the treatment of a variety of disease states. (C) 2001 Elsevier Science Ltd. All rights reserved

M3 - Literature review

VL - 38

SP - 249

EP - 255

JO - Molecular Immunology

JF - Molecular Immunology

IS - 2-3

ER -

Membrane-targeted complement inhibitors

Abstract

UN SDGs

Fingerprint

Cite this